Point72 Asset Management L.P. Acquires 24,560 Shares of Pediatrix Medical Group, Inc. (NYSE:MD)

Point72 Asset Management L.P. raised its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 663.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 28,260 shares of the company’s stock after acquiring an additional 24,560 shares during the period. Point72 Asset Management L.P.’s holdings in Pediatrix Medical Group were worth $213,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. nVerses Capital LLC acquired a new stake in shares of Pediatrix Medical Group during the second quarter worth $31,000. Innealta Capital LLC bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at about $33,000. Nisa Investment Advisors LLC increased its stake in shares of Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after acquiring an additional 1,524 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at approximately $72,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Pediatrix Medical Group during the 2nd quarter worth approximately $81,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

Insider Buying and Selling

In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the transaction, the chief executive officer now directly owns 170,001 shares in the company, valued at $1,834,310.79. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO James D. Swift sold 11,100 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the transaction, the chief executive officer now directly owns 170,001 shares in the company, valued at $1,834,310.79. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO C Marc Richards sold 32,562 shares of the firm’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $10.08, for a total transaction of $328,224.96. Following the completion of the sale, the chief financial officer now owns 192,785 shares of the company’s stock, valued at $1,943,272.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 68,100 shares of company stock worth $701,889. Corporate insiders own 2.00% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on MD. StockNews.com raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. Jefferies Financial Group raised Pediatrix Medical Group from a “hold” rating to a “buy” rating and boosted their target price for the company from $8.00 to $14.00 in a research note on Thursday, September 26th. UBS Group lifted their price objective on Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a report on Friday, August 9th. Finally, Truist Financial boosted their price objective on Pediatrix Medical Group from $8.00 to $10.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $10.30.

Pediatrix Medical Group Stock Up 1.9 %

Shares of Pediatrix Medical Group stock opened at $12.13 on Friday. Pediatrix Medical Group, Inc. has a 52-week low of $6.62 and a 52-week high of $13.01. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.38. The business’s 50 day simple moving average is $10.45 and its 200 day simple moving average is $8.97. The firm has a market cap of $1.02 billion, a PE ratio of -14.27, a P/E/G ratio of 1.74 and a beta of 1.56.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Tuesday, August 6th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.03. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The business had revenue of $504.30 million during the quarter, compared to the consensus estimate of $505.49 million. During the same quarter last year, the firm earned $0.37 earnings per share. The firm’s revenue for the quarter was up .7% compared to the same quarter last year. On average, analysts predict that Pediatrix Medical Group, Inc. will post 1.19 earnings per share for the current fiscal year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.